Between October 18–21, this website will move to a new web address (from health.gov to odphp.health.gov). During that time, some functions might not work as expected. We appreciate your patience and understanding as we’re working to make this transition as smooth as possible.

U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Celecoxib for Rheumatoid Arthritis

About this resource:

Systematic review

Source: The Cochrane Collaborative

Last Reviewed: June 2017

Workgroups: Arthritis Workgroup

In this Cochrane systematic review, the Cochrane Collaborative found that celecoxib, a selective non-steroidal anti-inflammatory drug (NSAID), may ease pain in people with rheumatoid arthritis (RA). The review included trials that compared celecoxib with a placebo or a traditional NSAID for people with RA (mostly women). Researchers found that after 12 weeks, people who took celecoxib had less pain than people who took a placebo and that results about physical function improvements were inconclusive in these groups. In studies comparing celecoxib to traditional NSAIDs, results about improvements in pain and physical function were also inconclusive.

Read more about this resource

Objectives related to this resource (1)

Reduce the proportion of adults with arthritis who have moderate or severe joint pain — A‑01
Little or no detectable change

Suggested Citation

1.

Fidahic,  M., Jelicic Kadic,  A., Radic,  M. & Puljak,  L. Celecoxib for rheumatoid arthritis. Cochrane Database of Systematic Reviews, 2017 (6). DOI: 10.1002/14651858.CD012095.pub2.